Proteostasis Therapeutics Inc. (PTI)

4.71
Prev Close 4.83
Day Low/High 4.70 / 4.86
52 Wk Low/High 1.41 / 8.61
Avg Volume 2.01M
Exchange
Shares Outstanding 36.08M
Market Cap 174.27M
EPS -2.30
Div & Yield N.A. (N.A)

Latest News

Glancy Prongay & Murray LLP Announces Investigation On Behalf Of Proteostasis Therapeutics, Inc. Investors (PTI)

Glancy Prongay & Murray LLP Announces Investigation On Behalf Of Proteostasis Therapeutics, Inc. Investors (PTI)

Glancy Prongay & Murray LLP ("GPM") announces an investigation on behalf of Proteostasis Therapeutics, Inc.

Proteostasis Therapeutics Announces FDA Grants Breakthrough Therapy Designation For PTI-428 In Cystic Fibrosis

Proteostasis Therapeutics Announces FDA Grants Breakthrough Therapy Designation For PTI-428 In Cystic Fibrosis

Designation granted for PTI-428 for the treatment of CF patients based on the results from a recent Phase 2, randomized, placebo controlled study

That Wild Market Momentum Has Cooled

That Wild Market Momentum Has Cooled

But here are some movers I am looking at today.

Proteostasis Therapeutics Reports Preliminary Data From Phase 1 Study Of PTI-428 In Patients With Cystic Fibrosis

Proteostasis Therapeutics Reports Preliminary Data From Phase 1 Study Of PTI-428 In Patients With Cystic Fibrosis

Screening Initiated in Phase 2 Portion of PTI-428 Study, 28-day Dosing Cohort

Proteostasis Therapeutics Announces Clinical And Regulatory Progress Across Pipeline Programs

Updates Announced During the 40th European Cystic Fibrosis Society Conference

TheStreet Quant Rating: D (Sell)